title: Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy.
abstract: To evaluate the effects of the iron chelator deferoxamine on the functional and structural manifestations of iron-induced cardiac dysfunction, we measured cardiac power, left ventricular systolic, and diastolic function as (dP/dt)max and (dP/dt)min, respectively, and left ventricular and septal wall thickness in isolated heart preparations derived from the Mongolian gerbil model of iron overload. We induced iron overload with weekly subcutaneous injections of iron dextran (800 mg/kg/wk); deferoxamine (DFO; 100 mg/kg) was administered twice daily by subcutaneous injection, 5 of 7 days each week; and control animals received weekly subcutaneous injections of dextran alone. Animals administered iron alone initially exhibited, at 5 weeks, increased cardiac power but by 12 to 20 weeks, cardiac power was severely diminished, with impairment of both systolic and diastolic function of the left ventricle and marked cardiac hypertrophy (P<.001 for all vs control animals). Administration of DFO with iron did not interfere with the initial augmentation of cardiac power at 5 weeks but prevented the subsequent deterioration in cardiac performance. After 12 to 20 weeks, gerbils given DFO with iron had mean values of cardiac power indistinguishable from those of control animals; both systolic and diastolic function were significantly enhanced not only in comparison with those of animals treated with iron alone but also with respect to controls. In addition, DFO prevented cardiac hypertrophy; mean ventricular and septal wall thickness in gerbils given DFO and iron were not significantly different from those in controls. In the gerbil model of iron overload, concurrent administration of DFO with iron prevents both the development of cardiac hypertrophy and the progressive deterioration in cardiac performance that are produced by chronic iron accumulation.
authors.affiliation: Department of Physiology and Biophysics, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
authors.forename: Tianen
authors.initials: T
authors.lastname: Yang
authors.forename: Gary M
authors.initials: GM
authors.lastname: Brittenham
authors.forename: Wei-Qiang
authors.initials: WQ
authors.lastname: Dong
authors.forename: Matthew N
authors.initials: MN
authors.lastname: Levy
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Obejero-Paz
authors.forename: Yuri A
authors.initials: YA
authors.lastname: Kuryshev
authors.forename: Arthur M
authors.initials: AM
authors.lastname: Brown
mesh_terms: D000818:Animals; D006332:Cardiomegaly / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control*; D009202:Cardiomyopathies / Q000188:drug therapy / Q000473:pathology / Q000517:prevention & control; D003676:Deferoxamine / Q000494:pharmacology*; D005260:Female; D005849:Gerbillinae; D006333:Heart Failure / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control*; D007501:Iron / Q000494:pharmacology; D007502:Iron Chelating Agents / Q000494:pharmacology*; D019190:Iron Overload / Q000150:complications; D009200:Myocardial Contraction / Q000187:drug effects
chemical_list: D007502:Iron Chelating Agents; D007501:Iron; D003676:Deferoxamine